Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9868972 | 0.74 | ROCK1 (0.47) | ROCK1LMNATP53MAPK1ALDH1A1 | |
| SCHEMBL29542545 | 0.74 | ALDH1A1 (0.53) | ROCK1LMNATP53MAPK1ALDH1A1 | |
| SCHEMBL3905172 | 0.74 | ALDH1A1 (0.53) | ROCK1LMNATP53MAPK1ALDH1A1 | |
| SCHEMBL29721693 | 0.73 | ROCK1 (0.61) | ROCK1LMNATP53MAPK1ALDH1A1 | |
| SCHEMBL3239758 | 0.73 | ROCK1 (0.61) | ROCK1LMNATP53MAPK1ALDH1A1 | |
| SCHEMBL19117986 | 0.72 | SRD5A1 (0.56) | ROCK1LMNATP53MAPK1ALDH1A1 | |
| SCHEMBL8938754 | 0.72 | LMNA (0.53) | ROCK1LMNATP53MAPK1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27693256 | 0.72 | ROCK1 (0.59) | ROCK1LMNATP53MAPK1ALDH1A1 | |
| SCHEMBL550432 | 0.72 | ROCK1 (0.44) | ROCK1LMNATP53MAPK1ALDH1A1 | |
| SCHEMBL22944577 | 0.71 | DRD2 (0.46) | ROCK1LMNATP53MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1881823-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | SARCODE CORP (US) | 2009-06-17 | — | — | EP | claimed |
| EP-1881823-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | Sarcode Corporation (US) | 2008-01-30 | — | — | EP | claimed |
| US-20060281739-A1 | Compositions and methods for treatment of eye disorders | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2006-12-14 | — | — | US | claimed |
| WO-2006125119-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | SARCODE CORPORATION (US) | 2006-11-23 | — | — | WO | claimed |
| JP-2002509881-A | — | — | 2002-04-02 | — | — | JP | claimed |
| EP-1063982-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | Genentech, Inc. (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999049856-A2 | ANTAGONISTS FOR TREATMENT OF CD11/CD18 ADHESION RECEPTOR MEDIATED DISORDERS | GENENTECH, INC. (US) | 1999-10-07 | — | — | WO | claimed |
| EP-3797775-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | Novartis AG (CH) | 2021-03-31 | — | — | EP | disclosed |
| EP-3167886-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA | NOVARTIS AG (CH) | 2020-08-05 | — | — | EP | disclosed |
| EP-3195861-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DRY EYE DISORDERS | SARcode Bioscience Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| EP-3167886-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF MACULAR EDEMA | SARcode Bioscience Inc. (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2209371-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE BIOSCIENCE INC (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2444079-B1 | Compositions and Methods for Treatment of Eye Disorders | SARCODE BIOSCIENCE INC (US) | 2016-11-30 | — | — | EP | disclosed |
| EP-2444079-A1 | Compositions and Methods for Treatment of Eye Disorders | SARcode Bioscience Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| EP-2209371-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | Sarcode Corporation (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-1881823-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | SARCODE CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009054914-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DIABETIC RETINOPATHY | SARCODE CORPORATION (US) | 2009-04-30 | — | — | WO | disclosed |
| EP-1881823-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | Sarcode Corporation (US) | 2008-01-30 | — | — | EP | disclosed |
| US-20060281739-A1 | Compositions and methods for treatment of eye disorders | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2006-12-14 | — | — | US | disclosed |
| WO-2006125119-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF EYE DISORDERS | SARCODE CORPORATION (US) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281739-A1 | Compositions and methods for treatment of eye disorders | ICAM1, VCAM1, ITGAL | ROCK1 643/4885LMNA 2218/4885TP53 3607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.